These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28546528)

  • 81. Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma.
    Chen Y; Quan L; Jia C; Guo Y; Wang X; Zhang Y; Jin Y; Liu A
    J Proteome Res; 2021 May; 20(5):2673-2686. PubMed ID: 33650432
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles.
    Borisov N; Sergeeva A; Suntsova M; Raevskiy M; Gaifullin N; Mendeleeva L; Gudkov A; Nareiko M; Garazha A; Tkachev V; Li X; Sorokin M; Surin V; Buzdin A
    Front Oncol; 2021; 11():652063. PubMed ID: 33937058
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma.
    Apipongrat D; Roytrakul S; Prayongratana K; Charoenpitakchai M; Intharanut K; Laoruangroj C; Silpsamrit P; Nathalang O
    PLoS One; 2022; 17(12):e0278464. PubMed ID: 36454786
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients.
    Ting KR; Henry M; Meiller J; Larkin A; Clynes M; Meleady P; Bazou D; Dowling P; O'Gorman P
    BBA Clin; 2017 Dec; 8():28-34. PubMed ID: 28725572
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma.
    Fall DJ; Stessman H; Patel SS; Sachs Z; Van Ness BG; Baughn LB; Linden MA
    J Cancer; 2014; 5(9):720-7. PubMed ID: 25368671
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Identification of pathway-based prognostic gene signatures in patients with multiple myeloma.
    Zamani-Ahmadmahmudi M; Dabiri S; Nadimi N
    Transl Res; 2017 Jul; 185():47-57. PubMed ID: 28549851
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The level of deletion 17p and bi-allelic inactivation of
    Thanendrarajan S; Tian E; Qu P; Mathur P; Schinke C; van Rhee F; Zangari M; Rasche L; Weinhold N; Alapat D; Bellamy W; Ashby C; Mattox S; Epstein J; Yaccoby S; Barlogie B; Hoering A; Bauer M; Walker BA; Davies FE; Morgan GJ
    Haematologica; 2017 Sep; 102(9):e364-e367. PubMed ID: 28550191
    [No Abstract]   [Full Text] [Related]  

  • 88. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
    Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
    Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
    Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
    Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
    Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
    Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Established and Novel Prognostic Biomarkers in Multiple Myeloma.
    Bustoros M; Mouhieddine TH; Detappe A; Ghobrial IM
    Am Soc Clin Oncol Educ Book; 2017; 37():548-560. PubMed ID: 28561668
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.
    Guang MHZ; McCann A; Bianchi G; Zhang L; Dowling P; Bazou D; O'Gorman P; Anderson KC
    Leuk Lymphoma; 2018 Mar; 59(3):542-561. PubMed ID: 28610537
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma.
    Wei G; Wang L; Yang H; Han X; Zheng G; Zheng W; Sun J; Shi J; Wu W; Zhao Y; He D; Wang B; Cai Z; He J
    Exp Hematol Oncol; 2017; 6():16. PubMed ID: 28560070
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Loss of
    Zhu YX; Shi CX; Bruins LA; Jedlowski P; Wang X; Kortüm KM; Luo M; Ahmann JM; Braggio E; Stewart AK
    Cancer Res; 2017 Aug; 77(16):4317-4327. PubMed ID: 28619709
    [No Abstract]   [Full Text] [Related]  

  • 95. MUC1-C is a target in lenalidomide resistant multiple myeloma.
    Yin L; Tagde A; Gali R; Tai YT; Hideshima T; Anderson K; Avigan D; Kufe D
    Br J Haematol; 2017 Sep; 178(6):914-926. PubMed ID: 28643330
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
    Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Doss D; Zaki MH; Bensmaine A; Herring J; Li Y; Watkins L; Chen MS; Anderson KC
    Leukemia; 2017 Dec; 31(12):2695-2701. PubMed ID: 28642620
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
    Moreb JS; Byrne M; Shugarman I; Zou F; Xiong S; May WS; Norkin M; Hiemenz J; Brown R; Cogle C; Wingard JR; Hsu JW
    J Clin Apher; 2018 Feb; 33(1):29-37. PubMed ID: 28556233
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Haematological cancer: Where are we now with the treatment of multiple myeloma?
    Morgan GJ; Rasche L
    Nat Rev Clin Oncol; 2017 Aug; 14(8):461-462. PubMed ID: 28607521
    [No Abstract]   [Full Text] [Related]  

  • 99. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
    Podar K; Pecherstorfer M
    Expert Opin Pharmacother; 2017 Aug; 18(11):1061-1079. PubMed ID: 28604120
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.
    Kumar SK; Dimopoulos MA; Kastritis E; Terpos E; Nahi H; Goldschmidt H; Hillengass J; Leleu X; Beksac M; Alsina M; Oriol A; Cavo M; Ocio EM; Mateos MV; O'Donnell EK; Vij R; Lokhorst HM; van de Donk NWCJ; Min C; Mark T; Turesson I; Hansson M; Ludwig H; Jagannath S; Delforge M; Kyriakou C; Hari P; Mellqvist U; Usmani SZ; Dytfeld D; Badros AZ; Moreau P; Kim K; Otero PR; Lee JH; Shustik C; Waller D; Chng WJ; Ozaki S; Lee JJ; de la Rubia J; Eom HS; Rosinol L; Lahuerta JJ; Sureda A; Kim JS; Durie BGM
    Leukemia; 2017 Nov; 31(11):2443-2448. PubMed ID: 28620163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.